Hospitalized patients dying with SARS-CoV-2 infection—an analysis of patient characteristics and management in ICU and general ward of the LEOSS registry

BACKGROUND: COVID-19 is a severe disease with a high need for intensive care treatment and a high mortality rate in hospitalized patients. The objective of this study was to describe and compare the clinical characteristics and the management of patients dying with SARS-CoV-2 infection in the acute medical and intensive care setting. METHODS: Descriptive analysis of dying patients enrolled in the Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS), a non-interventional cohort study, between March 18 and November 18, 2020. Symptoms, comorbidities and management of patients, including palliative care involvement, were compared between general ward and intensive care unit (ICU) by univariate analysis. RESULTS: 580/4310 (13%) SARS-CoV-2 infected patients died. Among 580 patients 67% were treated on ICU and 33% on a general ward. The spectrum of comorbidities and symptoms was broad with more comorbidities (≥ four comorbidities: 52% versus 25%) and a higher age distribution (>65 years: 98% versus 70%) in patients on the general ward. 69% of patients were in an at least complicated phase at diagnosis of the SARS-CoV-2 infection with a higher proportion of patients in a critical phase or dying the day of diagnosis treated on ICU (36% versus 11%). While most patients admitted to ICU came from home (71%), patients treated on the general ward came likewise from home and nursing home (44% respectively) and were more frequently on palliative care before admission (29% versus 7%). A palliative care team was involved in dying patients in 15%. Personal contacts were limited but more often documented in patients treated on ICU (68% versus 47%). CONCLUSION: Patients dying with SARS-CoV-2 infection suffer from high symptom burden and often deteriorate early with a demand for ICU treatment. Therefor a demand for palliative care expertise with early involvement seems to exist

Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort

Establishing the optimal treatment for COVID-19 patients remains challenging. Specifically, immunocompromised and pre-diseased patients are at high risk for severe disease course and face limited therapeutic options. Convalescent plasma (CP) has been considered as therapeutic approach, but reliable data are lacking, especially for high-risk patients. We performed a retrospective analysis of 55 hospitalized COVID-19 patients from University Hospital Duesseldorf (UKD) at high risk for disease progression, in a substantial proportion due to immunosuppression from cancer, solid organ transplantation, autoimmune disease, dialysis. A matched-pairs analysis (1:4) was performed with 220 patients from the Lean European Open Survey on SARS-CoV-2-infected Patients (LEOSS) who were treated or not treated with CP. Both cohorts had high mortality (UKD 41.8%, LEOSS 34.1%). A matched-pairs analysis showed no significant effect on mortality. CP administration before the formation of pulmonary infiltrates showed the lowest mortality in both cohorts (10%), whereas mortality in the complicated phase was 27.8%. CP administration during the critical phase revealed the highest mortality: UKD 60.9%, LEOSS 48.3%. In our cohort of COVID-19 patients with severe comorbidities CP did not significantly reduce mortality in a retrospective matched-pairs analysis. However, our data supports the concept that a reduction in mortality is achievable by early CP administration

Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort

Establishing the optimal treatment for COVID-19 patients remains challenging. Specifically, immunocompromised and pre-diseased patients are at high risk for severe disease course and face limited therapeutic options. Convalescent plasma (CP) has been considered as therapeutic approach, but reliable data are lacking, especially for high-risk patients. We performed a retrospective analysis of 55 hospitalized COVID-19 patients from University Hospital Duesseldorf (UKD) at high risk for disease progression, in a substantial proportion due to immunosuppression from cancer, solid organ transplantation, autoimmune disease, dialysis. A matched-pairs analysis (1:4) was performed with 220 patients from the Lean European Open Survey on SARS-CoV-2-infected Patients (LEOSS) who were treated or not treated with CP. Both cohorts had high mortality (UKD 41.8%, LEOSS 34.1%). A matched-pairs analysis showed no significant effect on mortality. CP administration before the formation of pulmonary infiltrates showed the lowest mortality in both cohorts (10%), whereas mortality in the complicated phase was 27.8%. CP administration during the critical phase revealed the highest mortality: UKD 60.9%, LEOSS 48.3%. In our cohort of COVID-19 patients with severe comorbidities CP did not significantly reduce mortality in a retrospective matched-pairs analysis. However, our data supports the concept that a reduction in mortality is achievable by early CP administration.Open Access funding enabled and organized by Projekt DEAL.Forschungsnetzwerk der Universitätsmedizin zu COVID-19German Centre for Infection Research (DZIF)Willy Robert Pitzer FoundationUniversitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts (8911

Covid-19 triage in the emergency department 2.0: how analytics and AI transform a human-made algorithm for the prediction of clinical pathways

The Covid-19 pandemic has pushed many hospitals to their capacity limits. Therefore, a triage of patients has been discussed controversially primarily through an ethical perspective. The term triage contains many aspects such as urgency of treatment, severity of the disease and pre-existing conditions, access to critical care, or the classification of patients regarding subsequent clinical pathways starting from the emergency department. The determination of the pathways is important not only for patient care, but also for capacity planning in hospitals. We examine the performance of a human-made triage algorithm for clinical pathways which is considered a guideline for emergency departments in Germany based on a large multicenter dataset with over 4,000 European Covid-19 patients from the LEOSS registry. We find an accuracy of 28 percent and approximately 15 percent sensitivity for the ward class. The results serve as a benchmark for our extensions including an additional category of palliative care as a new label, analytics, AI, XAI, and interactive techniques. We find significant potential of analytics and AI in Covid-19 triage regarding accuracy, sensitivity, and other performance metrics whilst our interactive human-AI algorithm shows superior performance with approximately 73 percent accuracy and up to 76 percent sensitivity. The results are independent of the data preparation process regarding the imputation of missing values or grouping of comorbidities. In addition, we find that the consideration of an additional label palliative care does not improve the results

Influence of Staphylococcus aureus on endothelial permeability in Ea.hy926 cells

Staphylococcus aureus (S. aureus) ist einer der häufigsten Erreger schwerer endovaskulärer Infektionen, die häufig mit einer Dissemination des Erregers in andere Organe und lebensbedrohlichen Komplikationen wie Endokarditis, Osteomyelitis oder Abszessen assoziiert sind. Entscheidender Schritt in der Pathogenese endovaskulärer Infektionen ist die Schädigung und Überwindung der Endothelbarriere. Für deren Integrität ist die Intaktheit von Zell-Zell-Verbindungen elementar, diese werden unter anderem durch Src-Kinasen reguliert. Es ist bekannt, dass S. aureus Fibronektin-Bindeproteine (FnBPs) maßgeblich für die Adhärenz und Invasion des Erregers in Endothelzellen sind. Die Invasion erfolgt über eine indirekte Bindung an α5β1-Integrine, invasive Eigenschaften finden sich in nahezu allen klinischen Isolaten. In verschiedenen Tiermodellen konnte außerdem ein Zusammenhang zwischen der Expression von FnBPs und der Dissemination von S. aureus in andere Organe gezeigt werden. Bislang ist jedoch nicht untersucht, welche Auswirkung die S. aureus-Infektion auf die Endothelbarriere hat und welche Mechanismen für die Translokation des Erregers verantwortlich sind. In dieser Arbeit wurde analysiert, ob die Infektion mit S. aureus- und S. carnosus-Stämmen in vitro zu einer Schädigung der endothelialen Integrität von EA.hy926-Zellen führt. Hierzu wurden Änderungen der transendothelialen Impedanz und der Endothelpermeabeabilität nach Infektion im xCELLigence- bzw. Transwell-System erfasst. Zytotoxische Effekte wurden durch Kristallviolettfärbungen, immunfluoreszenz-mikroskopische Untersuchungen der Mitochondrien und Nuklei sowie die Erfassung der hypodiploiden Zellkerne mittels Durchflusszytometrie quantifiziert. Zur Entschlüsselung des molekularen Mechanismus wurden Veränderungen der Adherens und Tight Junction-Proteine ZO-1 und VE-Cadherin in der Immunfluoreszenz untersucht. Die Rolle von Src-Kinasen wurde durch pharmakologische Inhibition analysiert. Es konnte gezeigt werden, dass FnBP-exprimierende S. aureus-Stämme eine Abnahme der transendothelialen Impedanz verursachen und dass es 4 und 24 Stunden nach Infektion zu einer signifikanten Zunahme der Endothelpermeabilität kommt. Zytotoxische Effekte auf die Endothelzellen durch die Infektion traten nach 24 Stunden auf, jedoch nicht nach 4 Stunden. VE-Cadherin und ZO-1 zeigten 4 Stunden nach Infektion eine FnBP-abhängige Konformationsänderung und Reduktion der Signalintensität. Außerdem konnte demonstriert werden, dass die Inhibition von Src-Kinasen den Anstieg der Endothelpermeabilität signifikant reduziert. In dieser Arbeit wurde zum ersten Mal belegt, dass S. aureus FnBPs eine Erhöhung der Endothelpermeabilität bewirken. Während hierfür zu späten Zeitpunkten Apoptose verantwortlich ist, muss nach 4 Stunden ein anderer Mechanismus ursächlich sein. Da es zu einer Abschwächung der ZO-1- und VE-Cadherin-Signalintensität in der Immunfluoreszenz kam, ist anzunehmen, dass Adherens und Tight Junctions durch die Infektion geschädigt werden. Es ist bekannt, dass Src-Kinasen durch die Infektion mit S. aureus aktiviert werden. Außerdem sind sie elementar für die Regulation der Endothelpermeabilität und vermitteln diesen Effekt unter anderem über eine Phosphorylierung von Adherens und Tight Junction-Proteinen. Eine Src-vermittelte Phosphorylierung von Zell-Zell-Verbindungsproteinen wäre daher eine mögliche Erklärung für die beobachteten Veränderungen von ZO-1 und VE-Cadherin. Dieser Mechanismus könnte Wegbereiter für die parazelluläre Passage über die Endothelbarriere sein. Darüber hinaus könnte die erhöhte Endothelpermeabilität den Zugang zur Extrazellulärematrix und zum größten Pool an Fibronektin und Integrinen ermöglichen und so die Invasion und Transzytose begünstigen. Die hier gewonnenen Ergebnisse tragen dazu bei, die komplexe Interaktion zwischen S. aureus und dem Endothel und somit wichtige Schritte in der Pathogenese endovaskulärer Infektionen besser zu verstehen und neue Zielstrukturen für therapeutische Interventionen zu identifizieren.Staphylococcus aureus (S. aureus) is a major cause of severe endovascular infections which are frequently associated with bacterial dissemination to other organs and life-threatening complications such as infective endocarditis, osteomyelitis or abscess formation. Damage to the endothelial barrier and bacterial extravasation are of vital importance in development of endovascular infections. Intercellular junctions are crucial for the integrity of the endothelial barrier; they are partially regulated by Src Family Protein-tyrosine Kinases. It has been well characterized that S. aureus fibronectin-binding proteins (FnBP) are decisive for adherence to and invasion of endothelial cells. Invasion is mediated by indirect bridging of fibronectin to α5β1-integrins via FnBPs. Invasive characteristics can be found in nearly all clinical isolates. Moreover, the link between expression of FnBPs and S. aureus dissemination into surrounding tissues has been demonstrated repeatedly in animal models. Despite the importance of S. aureus in endovascular diseases, the effect of S. aureus infection on endothelial barrier function and putative mechanisms for translocation have not yet been studied. The aim of this thesis was to evaluate whether infection with different S. aureus and S. carnosus strains leads to impairment of endothelial integrity in EA.hy926 cells. Changes in transendothelial impedance and endothelial permeability upon infection were measured using the xCELLigence- or transwell-system respectively. Cytotoxic effects were quantified by crystal violet staining, immunofluorescence staining of nuclei and mitochondria as well as by detection of hypodiploid nuclei using flow cytometry. Immunofluorescence staining of ZO-1 and VE—Cadherin was performed to investigate morphological alterations in intercellular junctions. The role of Src Family Protein-tyrosine Kinases was analyzed by pharmacological inhibition. In this study it was demonstrated that S. aureus strains expressing FnBPs lead to a decrease in transendothelial impedance and cause a significant increase in endothelial permeability 4 and 24 hours after infection. Whereas cytotoxic effects were observed after 24 hours, cells were completely viable 4 hours after infection. After 4 hours FnBP-dependent conformational changes of VE-cadherin and ZO-1 as well as a loss of signal intensity were detected. Furthermore, the FnBP-mediated increase in endothelial permeability was significantly reduced by using Src Family Protein-tyrosine Kinases-inhibitors. In this study it was shown for the first time that S. aureus FnBPs cause an increase in endothelial permeability. While apoptosis is the underlying mechanism 24 hours after infection, other mechanisms could be identified for the time point 4 hours. Since a loss of signal intensity of ZO-1 and VE-Cadherin was detected, it can be assumed that adherence and tight junctions are impaired upon infection. It has been well characterized that Src Family Protein-tyrosine Kinases are activated upon S. aureus infection and that they are decisive in regulation of endothelial permeability. This effect is mediated by phosphorylation of adherence and tight junction proteins. Hence a Src Family Protein-tyrosine Kinase-mediated phosphorylation of intercellular junction proteins is a conceivable mechanism for the observed change in ZO-1 and VE-cadherin, thus possibly enabling paracellular traverse of the endothelial barrier. On the other hand the increase of endothelial permeability could facilitate access to the extracellular matrix and thus to the biggest pool of fibronectin and integrins, hence promoting bacterial invasion and transcytosis. The obtained results help to understand the complex interaction between S. aureus and endothelial barrier, thus facilitating the understanding of the pathogenesis of endovascular S. aureus infections and possibly identifying new therapy targets

Auswirkungen von Staphylococcus aureus auf die Endothelpermeabilität in Ea.hy926-Zellen

Staphylococcus aureus (S. aureus) ist einer der häufigsten Erreger schwerer endovaskulärer Infektionen, die häufig mit einer Dissemination des Erregers in andere Organe und lebensbedrohlichen Komplikationen wie Endokarditis, Osteomyelitis oder Abszessen assoziiert sind. Entscheidender Schritt in der Pathogenese endovaskulärer Infektionen ist die Schädigung und Überwindung der Endothelbarriere. Für deren Integrität ist die Intaktheit von Zell-Zell-Verbindungen elementar, diese werden unter anderem durch Src-Kinasen reguliert. Es ist bekannt, dass S. aureus Fibronektin-Bindeproteine (FnBPs) maßgeblich für die Adhärenz und Invasion des Erregers in Endothelzellen sind. Die Invasion erfolgt über eine indirekte Bindung an α5β1-Integrine, invasive Eigenschaften finden sich in nahezu allen klinischen Isolaten. In verschiedenen Tiermodellen konnte außerdem ein Zusammenhang zwischen der Expression von FnBPs und der Dissemination von S. aureus in andere Organe gezeigt werden. Bislang ist jedoch nicht untersucht, welche Auswirkung die S. aureus-Infektion auf die Endothelbarriere hat und welche Mechanismen für die Translokation des Erregers verantwortlich sind. In dieser Arbeit wurde analysiert, ob die Infektion mit S. aureus- und S. carnosus-Stämmen in vitro zu einer Schädigung der endothelialen Integrität von EA.hy926-Zellen führt. Hierzu wurden Änderungen der transendothelialen Impedanz und der Endothelpermeabeabilität nach Infektion im xCELLigence- bzw. Transwell-System erfasst. Zytotoxische Effekte wurden durch Kristallviolettfärbungen, immunfluoreszenz-mikroskopische Untersuchungen der Mitochondrien und Nuklei sowie die Erfassung der hypodiploiden Zellkerne mittels Durchflusszytometrie quantifiziert. Zur Entschlüsselung des molekularen Mechanismus wurden Veränderungen der Adherens und Tight Junction-Proteine ZO-1 und VE-Cadherin in der Immunfluoreszenz untersucht. Die Rolle von Src-Kinasen wurde durch pharmakologische Inhibition analysiert. Es konnte gezeigt werden, dass FnBP-exprimierende S. aureus-Stämme eine Abnahme der transendothelialen Impedanz verursachen und dass es 4 und 24 Stunden nach Infektion zu einer signifikanten Zunahme der Endothelpermeabilität kommt. Zytotoxische Effekte auf die Endothelzellen durch die Infektion traten nach 24 Stunden auf, jedoch nicht nach 4 Stunden. VE-Cadherin und ZO-1 zeigten 4 Stunden nach Infektion eine FnBP-abhängige Konformationsänderung und Reduktion der Signalintensität. Außerdem konnte demonstriert werden, dass die Inhibition von Src-Kinasen den Anstieg der Endothelpermeabilität signifikant reduziert. In dieser Arbeit wurde zum ersten Mal belegt, dass S. aureus FnBPs eine Erhöhung der Endothelpermeabilität bewirken. Während hierfür zu späten Zeitpunkten Apoptose verantwortlich ist, muss nach 4 Stunden ein anderer Mechanismus ursächlich sein. Da es zu einer Abschwächung der ZO-1- und VE-Cadherin-Signalintensität in der Immunfluoreszenz kam, ist anzunehmen, dass Adherens und Tight Junctions durch die Infektion geschädigt werden. Es ist bekannt, dass Src-Kinasen durch die Infektion mit S. aureus aktiviert werden. Außerdem sind sie elementar für die Regulation der Endothelpermeabilität und vermitteln diesen Effekt unter anderem über eine Phosphorylierung von Adherens und Tight Junction-Proteinen. Eine Src-vermittelte Phosphorylierung von Zell-Zell-Verbindungsproteinen wäre daher eine mögliche Erklärung für die beobachteten Veränderungen von ZO-1 und VE-Cadherin. Dieser Mechanismus könnte Wegbereiter für die parazelluläre Passage über die Endothelbarriere sein. Darüber hinaus könnte die erhöhte Endothelpermeabilität den Zugang zur Extrazellulärematrix und zum größten Pool an Fibronektin und Integrinen ermöglichen und so die Invasion und Transzytose begünstigen. Die hier gewonnenen Ergebnisse tragen dazu bei, die komplexe Interaktion zwischen S. aureus und dem Endothel und somit wichtige Schritte in der Pathogenese endovaskulärer Infektionen besser zu verstehen und neue Zielstrukturen für therapeutische Interventionen zu identifizieren

Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma

AbstractA liquid chromatography tandem mass spectrometry method for the analysis of ten kinase inhibitors (afatinib, axitinib, bosutinib, cabozantinib, dabrafenib, lenvatinib, nilotinib, osimertinib, ruxolitinib, and trametinib) in human serum and plasma for the application in daily clinical routine has been developed and validated according to the US Food and Drug Administration and European Medicines Agency validation guidelines for bioanalytical methods. After protein precipitation of plasma samples with acetonitrile, chromatographic separation was performed at ambient temperature using a Waters XBridge® Phenyl 3.5 μm (2.1 × 50 mm) column. The mobile phases consisted of water-methanol (9:1, v/v) with 10 mM ammonium bicarbonate as phase A and methanol-water (9:1, v/v) with 10 mM ammonium bicarbonate as phase B. Gradient elution was applied at a flow rate of 400 μL/min. Analytes were detected and quantified using multiple reaction monitoring in electrospray ionization positive mode. Stable isotopically labeled compounds of each kinase inhibitor were used as internal standards. The acquisition time was 7.0 min per run. All analytes and internal standards eluted within 3.0 min. The calibration curves were linear over the range of 2–500 ng/mL for afatinib, axitinib, bosutinib, lenvatinib, ruxolitinib, and trametinib, and 6–1500 ng/mL for cabozantinib, dabrafenib, nilotinib, and osimertinib (coefficients of correlation ≥ 0.99). Validation assays for accuracy and precision, matrix effect, recovery, carryover, and stability were appropriate according to regulatory agencies. The rapid and sensitive assay ensures high throughput and was successfully applied to monitor concentrations of kinase inhibitors in patients.</jats:p

Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice—a prospective single-center trial

Abstract Purpose Knowledge on Ruxolitinib exposure in patients with graft versus host disease (GvHD) is scarce. The purpose of this prospective study was to analyze Ruxolitinib concentrations of GvHD patients and to investigate effects of CYP3A4 and CYP2C9 inhibitors and other covariates as well as concentration-dependent effects. Methods 262 blood samples of 29 patients with acute or chronic GvHD who were administered Ruxolitinib during clinical routine were analyzed. A population pharmacokinetic model obtained from myelofibrosis patients was adapted to our population and was used to identify relevant pharmacokinetic properties and covariates on drug exposure. Relationships between Ruxolitinib exposure and adverse events were assessed. Results Median of individual mean trough serum concentrations was 39.9 ng/mL at 10 mg twice daily (IQR 27.1 ng/mL, range 5.6–99.8 ng/mL). Applying a population pharmacokinetic model revealed that concentrations in our cohort were significantly higher compared to myelofibrosis patients receiving the same daily dose (p &lt; 0.001). Increased Ruxolitinib exposure was caused by a significant reduction in Ruxolitinib clearance by approximately 50%. Additional comedication with at least one strong CYP3A4 or CYP2C9 inhibitor led to a further reduction by 15% (p &lt; 0.05). No other covariate affected pharmacokinetics significantly. Mean trough concentrations of patients requiring dose reduction related to adverse events were significantly elevated (p &lt; 0.05). Conclusion Ruxolitinib exposure is increased in GvHD patients in comparison to myelofibrosis patients due to reduced clearance and comedication with CYP3A4 or CYP2C9 inhibitors. Elevated Ruxolitinib trough concentrations might be a surrogate for toxicity. </jats:sec